Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases

Current Pharmaceutical Biotechnology

Volumn 11, Issue 2, 2010, Pages 188-197

  Nagai, Yoshitaka ^a,b   Fujikake, Nobuhiro ^a   Popiel, H Akiko ^a   Wada, Keiji ^a,b  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Aggregation; Chaperone inducers; Heat shock transcription factor 1; Huntington's disease; Misfolding; Molecular chaperones; Neurodegenerative diseases; Polyglutamine diseases

Indexed keywords

CHAPERONE; HEAT SHOCK TRANSCRIPTION FACTOR 1;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MACHADO JOSEPH DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; SPINOCEREBELLAR DEGENERATION;

AMYLOID; ANIMALS; BRAIN; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; MOLECULAR CHAPERONES; PEPTIDES; PROTEIN FOLDING;

EID: 77949884097     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110790909650     Document Type: Review

References (114)

1. Young, J.C.; Agashe, V.R.; Siegers, K.; Hartl, F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol., 2004, 5(10), 781-791.
2. Liberek, K.; Lewandowska, A.; Zietkiewicz, S. Chaperones in control of protein disaggregation. EMBO J., 2008, 27(2), 328-335.
3. Glenner, G.G.; Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun., 1984, 120(3), 885-890.
4. Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y.C.; Zaidi, M.S.; Wisniewski, H.M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem., 1986, 261(13), 6084-6089.
5. Wischik, C.M.; Novak, M.; Thogersen, H.C.; Edwards, P.C.; Runswick, M.J.; Jakes, R.; Walker, J.E.; Milstein, C.; Roth, M.; Klug, A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1988, 85(12), 4506-4510.
6. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. α-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
7. Taylor, J.P.; Hardy, J.; Fischbeck, K.H. Toxic proteins in neurodegenerative disease. Science, 2002, 296(5575), 1991-1995.
8. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci., 2003, 4(1), 49-60.
9. Ross, C.A.; Poirier, M.A. Opinion: What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol., 2005, 6(11), 891-898.
10. Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Mant, R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericak-Vance, M.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 1991, 349(6311), 704-706.
11. Sherrington, R.; Rogaev, E.I.; Liang, Y.; Rogaeva, E.A.; Levesque, G.; Ikeda, M.; Chi, H.; Lin, C.; Li, G.; Holman, K.; Tsuda, T.; Mar, L.; Foncin, J.F.; Bruni, A.C.; Montesi, M.P.; Sorbi, S.; Rainero, I.; Pinessi, L.; Nee, L.; Chumakov, I.; Pollen, D.; Brookes, A.; Sanseau, P.; Polinsky, R.J.; Wasco, W.; Da Silva, H.A.R.; Haines, J.L.; Pericak-Vance, M.A.; Tanzi, R.E.; Roses, A.D.; Fraser, P.E.; Rommens, J.M.; St George-Hyslop, P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 1995, 375(6534), 754-760.
12. Levy-Lahad, E.; Wasco, W.; Poorkaj, P.; Romano, D.M.; Oshima, J.; Pettingell, W.H.; Yu, C.E.; Jondro, P.D.; Schmidt, S.D.; Wang, K.; Crowley, A.C.; Fu, Y.H.; Guenette, S.Y.; Galas, D.; Nemens, E.; Wijsman, E.M.; Bird, T.D.; Schellenberg, G.D.; Tanzi, R.E. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, 1995, 269(5226), 973-977.
13. Rogaev, E.I.; Sherrington, R.; Rogaeva, E.A.; Levesque, G.; Ikeda, M.; Liang, Y.; Chi, H.; Lin, C.; Holman, K.; Tsuda, T.; Mar, L.; Sorbi, S.; Nacmias, B.; Piacentini, S.; Amaducci, L.; Chumakov, I.; Cohen, D.; Lannfelt, L.; Fraser, P.E.; Rommens, J.M.; St George-Hyslop, P.H. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature, 1995, 376(6543), 775-778.
14. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
15. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276(5321), 2045-2047.
16. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. α-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302(5646), 841.
17. Waxman, E.A.; Giasson, B.I. Molecular mechanisms of α-synuclein neurodegeneration. Biochim. Biophys. Acta., 2009, 1792(7), 616-624.
18. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X.; Rahmani, Z.: Krizus, A.; McKenna-Yasek, D.; Cayabyab, A.; Gaston, S.M.; Berger, R.; Tanzi, R.E.; Halperin, J.J.; Herzfeldt, B.; Van den Bergh, R.; Hung, W.; Bird, T.; Deng, G.; Mulder, D.W.; Smyth, C.; Laing, N.G.; Soriano, E.; Pericak-Vance, M.A.; Haines, J.; Rouleau, G.A.; Gusella, J.S.; Horvitz, H.R.; Brown, R.H. Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362(6415), 59-62.
19. Sreedharan, J.; Blair, I.P.; Tripathi, V.B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.; Durnall, J.C.; Williams, K.L.; Buratti, E.; Baralle, F.; de Belleroche, J.; Mitchell, J.D.; Leigh, P.N.; Al-Chalabi, A.; Miller, C.C.; Nicholson, G.; Shaw, C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 2008, 319(5870), 1668-1672.
20. Hutton, M.; Lendon, C.L.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.; Isaacs, A.; Grover, A.; Hackett, J.; Adamson, J.; Lincoln, S.; Dickson, D.; Davies, P.; Petersen, R.C.; Stevens, M.; de Graaff, E.; Wauters, E.; van Baren, J.; Hillebrand, M.; Joosse, M.; Kwon, J.M.; Nowotny, P.; Che, L.K.; Norton, J.; Morris, J.C.; Reed, L.A.; Trojanowski, J.; Basun, H.; Lannfelt, L.; Neystat, M.; Fahn, S.; Dark, F.; Tannenberg, T.; Dodd, P.R.; Hayward, N.; Kwok, J.B.; Schofield, P.R.; Andreadis, A.; Snowden, J.; Craufurd, D.; Neary, D.; Owen, F.; Oostra, B.A.; Hardy, J.; Goate, A.; van Swieten, J.; Mann, D.; Lynch, T.; Heutink, P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393(6686), 702-705.
21. Spillantini, M.G.; Murrell, J.R.; Goedert, M.; Farlow, M.R.; Klug, A.; Ghetti, B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA, 1998, 95(13), 7737-7741.
22. Poorkaj, P.; Bird, T.D.; Wijsman, E.; Nemens, E.; Garruto, R.M.; Anderson, L.; Andreadis, A.; Wiederholt, W.C.; Raskind, M.; Schellenberg, G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol., 1998, 43(6), 815-825.
23. Baker, M.; Mackenzie, I.R.; Pickering-Brown, S.M.; Gass, J.; Rademakers, R.; Lindholm, C.; Snowden, J.; Adamson, J.; Sadovnick, A.D.; Rollinson, S.; Cannon, A.; Dwosh, E.; Neary, D.; Melquist, S.; Richardson, A.; Dickson, D.; Berger, Z.; Eriksen, J.; Robinson, T.; Zehr, C.; Dickey, C.A.; Crook, R.; McGowan, E.; Mann, D.; Boeve, B.; Feldman, H.; Hutton, M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442(7105), 916-919.
24. Cruts, M.; Gijselinck, I.; van der Zee, J.; Engelborghs, S.; Wils, H.; Pirici, D.; Rademakers, R.; Vandenberghe, R.; Dermaut, B.; Martin, J.J.; van Duijn, C.; Peeters, K.; Sciot, R.; Santens, P.; De Pooter, T.; Mattheijssens, M.; Van den Broeck, M.; Cuijt, I.; Vennekens, K.; De Deyn, P.P.; Kumar-Singh, S.; Van Broeckhoven, C. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 2006, 442(7105), 920-924.
25. Orr, H.T.; Zoghbi, H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci., 2007, 30, 575-621.
26. Nagai, Y.; Popiel, H.A. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed β-sheet hypothesis. Curr. Pharm. Des., 2008, 14(30), 3267-3279.
27. Bauer, P.O.; Nukina, N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem., 2009, 110(6), 1737-1765.
28. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 1993, 72(6), 971-983.
29. Orr, H.T.; Chung, M.Y.; Banfi, S.; Kwiatkowski, T.J., Jr.; Servadio, A.; Beaudet, A.L.; McCall, A.E.; Duvick, L.A.; Ranum, L.P.; Zoghbi, H.Y. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet., 1993, 4(3), 221-226.
30. Pulst, S.M.; Nechiporuk, A.; Nechiporuk, T.; Gispert, S.; Chen, X.N.; Lopes-Cendes, I.; Pearlman, S.; Starkman, S.; Orozco-Diaz, G.; Lunkes, A.; DeJong, P.; Rouleau, G.A.; Auburger, G.; Korenberg, J.R.; Figueroa, C.; Sahba, S. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet., 1996, 14(3), 269-276.
31. Sanpei, K.; Takano, H.; Igarashi, S.; Sato, T.; Oyake, M.; Sasaki, H.; Wakisaka, A.; Tashiro, K.; Ishida, Y.; Ikeuchi, T.; Koide, R.; Saito, M.; Sato, A.; Tanaka, T.; Hanyu, S.; Takiyama, Y.; Nishizawa, M.; Shimizu, N.; Nomura, Y.; Segawa, M.; Iwabuchi, K.; Eguchi, I.; Tanaka, H.; Takahashi, H.; Tsuji, S. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet., 1996, 14(3), 277-284.
32. Imbert, G.; Saudou, F.; Yvert, G.; Devys, D.; Trottier, Y.; Garnier, J.M.; Weber, C.; Mandel, J.L.; Cancel, G.; Abbas, N.; Durr, A.; Didierjean, O.; Stevanin, G.; Agid, Y.; Brice, A. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet., 1996, 14(3), 285-291.
33. Kawaguchi, Y.; Okamoto, T.; Taniwaki, M.; Aizawa, M.; Inoue, M.; Katayama, S.; Kawakami, H.; Nakamura, S.; Nishimura, M.; Akiguchi, I.; Kimura, J.; Narumiya, S.; Kakizuka, A. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet., 1994, 8(3), 221-228.
34. Zhuchenko, O.; Bailey, J.; Bonnen, P.; Ashizawa, T.; Stockton, D.W.; Amos, C.; Dobyns, W.B.; Subramony, S.H.; Zoghbi, H.Y.; Lee, C.C. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel. Nat. Genet., 1997, 15(1), 62-69.
35. David, G.; Abbas, N.; Stevanin, G.; Durr, A.; Yvert, G.; Cancel, G.; Weber, C.; Imbert, G.; Saudou, F.; Antoniou, E.; Drabkin, H.; Gemmill, R.; Giunti, P.; Benomar, A.; Wood, N.; Ruberg, M.; Agid, Y.; Mandel, J.L.; Brice, A. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat. Genet., 1997, 17(1), 65-70.
36. Nakamura, K.; Jeong, S.Y.; Uchihara, T.; Anno, M.; Nagashima, K.; Nagashima, T.; Ikeda, S.; Tsuji, S.; Kanazawa, I. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet., 2001, 10(14), 1441-1448.
37. Koide, R.; Ikeuchi, T.; Onodera, O.; Tanaka, H.; Igarashi, S.; Endo, K.; Takahashi, H.; Kondo, R.; Ishikawa, A.; Hayashi, T.; Saito, M.; Tomoda, A.; Miike, T.; Naito, H.; Ikuta, F.; Tsuji, S. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat. Genet., 1994, 6(1), 9-13.
38. Nagafuchi, S.; Yanagisawa, H.; Sato, K.; Shirayama, T.; Ohsaki, E.; Bundo, M.; Takeda, T.; Tadokoro, K.; Kondo, I.; Murayama, N; Tanaka, Y.; Kikushima, H.; Umino, K.; Kurosawa, H.; Furukawa, T.; Nihei, K.; Inoue, T.; Sano, A.; Komure, O.; Takahashi, M.; Yoshizawa, T.; Kanazawa, I.; Yamada, M. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat. Genet., 1994, 6(1), 14-18.
39. La Spada, A.R.; Wilson, E.M.; Lubahn, D.B.; Harding, A.E.; Fischbeck, K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature, 1991, 352(6330), 77-79.
40. Burright, E.N.; Clark, H.B.; Servadio, A.; Matilla, T.; Feddersen, R.M.; Yunis, W.S.; Duvick, L.A.; Zoghbi, H.Y.; Orr, H.T. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell, 1995, 82(6), 937-948.
41. Ikeda, H.; Yamaguchi, M.; Sugai, S.; Aze, Y.; Narumiya, S.; Kakizuka, A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet., 1996, 13(2), 196-202.
42. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S.W.; Bates, G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 1996, 87(3), 493-506.
43. Warrick, J.M.; Paulson, H.L.; Gray-Board, G.L.; Bui, Q.T.; Fischbeck, K.H.; Pittman, R.N.; Bonini, N.M. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell, 1998, 93(6), 939-949.
44. Faber, P.W.; Alter, J.R.; MacDonald, M.E.; Hart, A.C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. USA, 1999, 96(1), 179-184.
45. Shao, J.; Diamond, M.I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet., 2007, 16(Spec No. 2), R115-123.
46. Williams, A.J.; Paulson, H.L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci., 2008, 31(10), 521-528.
47. Schaffar, G.; Breuer, P.; Boteva, R.; Behrends, C.; Tzvetkov, N.; Strippel, N.; Sakahira, H.; Siegers, K.; Hayer-Hartl, M.; Hartl, F.U. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell, 2004, 15(1), 95-105.
48. Li, M.; Chevalier-Larsen, E.S.; Merry, D.E.; Diamond, M.I. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J. Biol. Chem., 2007, 282(5), 3157-3164.
49. Nagai, Y.; Inui, T.; Popiel, H.A.; Fujikake, N.; Hasegawa, K.; Urade, Y.; Goto, Y.; Naiki, H.; Toda, T. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol., 2007, 14(4), 332-340.
50. Takahashi, T.; Kikuchi, S.; Katada, S.; Nagai, Y.; Nishizawa, M.; Onodera, O. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet., 2008, 17(3), 345-356.
51. Davies, J.E.; Sarkar, S.; Rubinsztein, D.C. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem., 2007, 8(Suppl. 1), S2.
52. Li, X.; Li, H.; Li, X.J. Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Res. Rev., 2008, 59(1), 245-252.
53. Cummings, C.J.; Mancini, M.A.; Antalffy, B.; DeFranco, D.B.; Orr, H.T.; Zoghbi, H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet., 1998, 19(2), 148-154.
54. Chai, Y.; Koppenhafer, S.L.; Bonini, N.M.; Paulson, H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci., 1999, 19(23), 10338-10347.
55. Perez, M.K.; Paulson, H.L.; Pendse, S.J.; Saionz, S.J.; Bonini, N.M.; Pittman, R.N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell. Biol., 1998, 143(6), 1457-1470.
56. Shimohata, T.; Nakajima, T.; Yamada, M.; Uchida, C.; Onodera, O.; Naruse, S.; Kimura, T.; Koide, R.; Nozaki, K.; Sano, Y.; Ishiguro, H.; Sakoe, K.; Ooshima, T.; Sato, A.; Ikeuchi, T.; Oyake, M.; Sato, T.; Aoyagi, Y.; Hozumi, I.; Nagatsu, T.; Takiyama, Y.; Nishizawa, M.; Goto, J.; Kanazawa, I.; Davidson, I.; Tanese, N.; Takahashi, H.; Tsuji, S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet., 2000, 26(1), 29-36.
57. Nucifora, F.C., Jr.; Sasaki, M.; Peters, M.F.; Huang, H.; Cooper, J.K.; Yamada, M.; Takahashi, H.; Tsuji, S.; Troncoso, J.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science, 2001, 291(5512), 2423-2428.
58. Nagai, Y.; Onodera, O.; Chun, J.; Strittmatter, W.J.; Burke, J.R. Expanded polyglutamine domain proteins bind neurofilament and alter the neurofilament network. Exp. Neurol., 1999, 155(2), 195-203.
59. Muchowski, P.J.; Ning, K.; D'Souza-Schorey, C.; Fields, S. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl. Acad. Sci. USA, 2002, 99(2), 727-732.
60. DiProspero, N.A.; Chen, E.Y.; Charles, V.; Plomann, M.; Kordower, J.H.; Tagle, D.A. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol., 2004, 33(5), 517-533.
61. Bence, N.F.; Sampat, R.M.; Kopito, R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 2001, 292(5521), 1552-1555.
62. Steffan, J.S.; Bodai, L.; Pallos, J.; Poelman, M.; McCampbell, A.; Apostol, B.L.; Kazantsev, A.; Schmidt, E.; Zhu, Y.Z.; Greenwald, M.; Kurokawa, R.; Housman, D.E.; Jackson, G.R.; Marsh, J.L.; Thompson, L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 2001, 413(6857), 739-743.
63. Gunawardena, S.; Her, L.S.; Brusch, R.G.; Laymon, R.A.; Niesman, I.R.; Gordesky-Gold, B.; Sintasath, L.; Bonini, N.M.; Goldstein, L.S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron, 2003, 40(1), 25-40.
64. Szebenyi, G.; Morfini, G.A.; Babcock, A.; Gould, M.; Selkoe, K.; Stenoien, D.L.; Young, M.; Faber, P.W.; MacDonald, M.E.; McPhaul, M.J.; Brady, S.T. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron, 2003, 40(1), 41-52.
65. Di Prospero, N.A.; Fischbeck, K.H. Therapeutics development for triplet repeat expansion diseases. Nat. Rev. Genet., 2005, 6(10), 756-765.
66. Imarisio, S.; Carmichael, J.; Korolchuk, V.; Chen, C.W.; Saiki, S.; Rose, C.; Krishna, G.; Davies, J.E.; Ttofi, E.; Underwood, B.R.; Rubinsztein, D.C. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J., 2008, 412(2), 191-209.
67. Bates, G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet, 2003, 361(9369), 1642-1644.
68. Michalik, A.; Van Broeckhoven, C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum. Mol. Genet., 2003, 12(Spec No. 2), R173-186.
69. Herbst, M.; Wanker, E.E. Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation. Curr. Pharm. Des., 2006, 12(20), 2543-2555.
70. Stenoien, D.L.; Cummings, C.J.; Adams, H.P.; Mancini, M.G.; Patel, K.; DeMartino, G.N.; Marcelli, M.; Weigel, N.L.; Mancini, M.A. Polyglutamine- expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet., 1999, 8(5), 731-741.
71. Kobayashi, Y.; Kume, A.; Li, M.; Doyu, M.; Hata, M.; Ohtsuka, K.; Sobue, G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem., 2000, 275(12), 8772-8778.
72. Jana, N.R.; Tanaka, M.; Wang, G.; Nukina, N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet., 2000, 9(13), 2009-2018.
73. Warrick, J.M.; Chan, H.Y.; Gray-Board, G.L.; Chai, Y.; Paulson, H.L.; Bonini, N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet., 1999, 23(4), 425-428.
74. Kazemi-Esfarjani, P.; Benzer, S. Genetic suppression of polyglutamine toxicity in Drosophila. Science, 2000, 287(5459), 1837-1840.
75. Fernandez-Funez, P.; Nino-Rosales, M.L.; de Gouyon, B.; She, W.C.; Luchak, J.M.; Martinez, P.; Turiegano, E.; Benito, J.; Capovilla, M.; Skinner, P.J.; McCall, A.; Canal, I.; Orr, H.T.; Zoghbi, H.Y.; Botas, J. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature, 2000, 408(6808), 101-106.
76. Chan, H.Y.; Warrick, J.M.; Gray-Board, G.L.; Paulson, H.L.; Bonini, N.M. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum. Mol. Genet., 2000, 9(19), 2811-2820.
77. Muchowski, P.J.; Schaffar, G.; Sittler, A.; Wanker, E.E.; Hayer-Hartl, M.K.; Hartl, F.U. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA, 2000, 97(14), 7841-7846.
78. Cummings, C.J.; Sun, Y.; Opal, P.; Antalffy, B.; Mestril, R.; Orr, H.T.; Dillmann, W.H.; Zoghbi, H.Y. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet., 2001, 10(14), 1511-1518.
79. Adachi, H.; Katsuno, M.; Minamiyama, M.; Sang, C.; Pagoulatos, G.; Angelidis, C.; Kusakabe, M.; Yoshiki, A.; Kobayashi, Y.; Doyu, M.; Sobue, G. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci., 2003, 23(6), 2203-2211.
80. Hansson, O.; Nylandsted, J.; Castilho, R.F.; Leist, M.; Jaattela, M.; Brundin, P. Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Res., 2003, 970(1-2), 47-57.
81. Hay, D.G.; Sathasivam, K.; Tobaben, S.; Stahl, B.; Marber, M.; Mestril, R.; Mahal, A.; Smith, D.L.; Woodman, B.; Bates, G.P. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet., 2004, 13(13), 1389-1405.
82. Helmlinger, D.; Bonnet, J.; Mandel, J.L.; Trottier, Y.; Devys, D. Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice. J. Biol. Chem., 2004, 279(53), 55969-55977.
83. Wacker, J.L.; Huang, S.Y.; Steele, A.D.; Aron, R.; Lotz, G.P.; Nguyen, Q.; Giorgini, F.; Roberson, E.D.; Lindquist, S.; Masliah, E.; Muchowski, P.J. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J. Neurosci., 2009, 29(28), 9104-9114.
84. Wyttenbach, A.; Sauvageot, O.; Carmichael, J.; Diaz-Latoud, C.; Arrigo, A.P.; Rubinsztein, D.C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet., 2002, 11(9), 1137-1151.
85. Carra, S.; Sivilotti, M.; Chavez Z.A.T.; Lambert, H.; Landry, J. HspB8, a small heat shock protein mutated in human neuromuscular disorders, has in vivo chaperone activity in cultured cells. Hum. Mol. Genet., 2005, 14(12), 1659-1669.
86. Mitsui, K.; Nakayama, H.; Akagi, T.; Nekooki, M.; Ohtawa, K.; Takio, K.; Hashikawa, T.; Nukina, N. Purification of polyglutamine aggregates and identification of elongation factor-1α and heat shock protein 84 as aggregate-interacting proteins. J. Neurosci., 2002, 22(21), 9267-9277.
87. Ishihara, K.; Yamagishi, N.; Saito, Y.; Adachi, H.; Kobayashi, Y.; Sobue, G.; Ohtsuka, K.; Hatayama, T. Hsp105α suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity. J. Biol. Chem., 2003, 278(27), 25143-25150.
88. Behrends, C.; Langer, C.A.; Boteva, R.; Bottcher, U.M.; Stemp, M.J.; Schaffar, G.; Rao, B.V.; Giese, A.; Kretzschmar, H.; Siegers, K.; Hartl, F.U. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol. Cell, 2006, 23(6), 887-897.
89. Kitamura, A.; Kubota, H.; Pack, C.G.; Matsumoto, G.; Hirayama, S.; Takahashi, Y.; Kimura, H.; Kinjo, M.; Morimoto, R.I.; Nagata, K. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat. Cell Biol., 2006, 8(10), 1163-1170.
90. Tam, S.; Geller, R.; Spiess, C.; Frydman, J. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat. Cell Biol., 2006, 8(10), 1155-1162.
91. Jana, N.R.; Nukina, N. BAG-1 associates with the polyglutamine-expanded huntingtin aggregates. Neurosci. Lett., 2005, 378(3), 171-175.
92. Jana, N.R.; Dikshit, P.; Goswami, A.; Kotliarova, S.; Murata, S.; Tanaka, K.; Nukina, N. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem., 2005, 280(12), 11635-11640.
93. Miller, V.M.; Nelson, R.F.; Gouvion, C.M.; Williams, A.; Rodriguez-Lebron, E.; Harper, S.Q.; Davidson, B.L.; Rebagliati, M.R.; Paulson, H.L. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci., 2005, 25(40), 9152-9161.
94. Muchowski, P.J.; Wacker, J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci., 2005, 6(1), 11-22.
95. Broadley, S.A.; Hartl, F.U. The role of molecular chaperones in human misfolding diseases. FEBS Lett., 2009, 583(16), 2647-2653.
96. Kim, S.; Nollen, E.A.; Kitagawa, K.; Bindokas, V.P.; Morimoto, R.I. Polyglutamine protein aggregates are dynamic. Nat. Cell Biol., 2002, 4(10), 826-831.
97. Yamanaka, T.; Miyazaki, H.; Oyama, F.; Kurosawa, M.; Washizu, C.; Doi, H.; Nukina, N. Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J., 2008, 27(6), 827-839.
98. Huen, N.Y.; Chan, H.Y. Dynamic regulation of molecular chaperone gene expression in polyglutamine disease. Biochem. Biophys. Res. Commun., 2005, 334(4), 1074-1084.
99. Tagawa, K.; Marubuchi, S.; Qi, M.L.; Enokido, Y.; Tamura, T.; Inagaki, R.; Murata, M.; Kanazawa, I.; Wanker, E.E.; Okazawa, H. The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes. J. Neurosci., 2007, 27(4), 868-880.
100. Li, Q.; Herrler, M.; Landsberger, N.; Kaludov, N.; Ogryzko, V.V.; Nakatani, Y.; Wolffe, A.P. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J., 1998, 17(21), 6300-6315.
101. Pirkkala, L.; Nykanen, P.; Sistonen, L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J., 2001, 15(7), 1118-1131.
102. Morimoto, R.I. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev., 2008, 22(11), 1427-1438.
103. Rimoldi, M.; Servadio, A.; Zimarino, V. Analysis of heat shock transcription factor for suppression of polyglutamine toxicity. Brain Res. Bull., 2001, 56(3-4), 353-362.
104. Fujimoto, M.; Takaki, E.; Hayashi, T.; Kitaura, Y.; Tanaka, Y.; Inouye, S.; Nakai, A. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem., 2005, 280(41), 34908-34916.
105. Naiki, H.; Nagai, Y. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. J. Biochem., 2009, 146(6), 751-756.
106. Sittler, A.; Lurz, R.; Lueder, G.; Priller, J.; Lehrach, H.; Hayer-Hartl, M.K.; Hartl, F.U.; Wanker, E.E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet., 2001, 10(12), 1307-1315.
107. Katsuno, M.; Sang, C.; Adachi, H.; Minamiyama, M.; Waza, M.; Tanaka, F.; Doyu, M.; Sobue, G. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl. Acad. Sci. USA, 2005, 102(46), 16801-16806.
108. Otaka, M.; Yamamoto, S.; Ogasawara, K.; Takaoka, Y.; Noguchi, S.; Miyazaki, T.; Nakai, A.; Odashima, M.; Matsuhashi, T.; Watanabe, S.; Itoh, H. The induction mechanism of the molecular chaperone HSP70 in the gastric mucosa by Geranylgeranylacetone (HSP-inducer). Biochem. Biophys. Res. Commun., 2007, 353(2), 399-404.
109. Herbst, M.; Wanker, E.E. Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy. Neurodegener. Dis., 2007, 4(2-3), 254-260.
110. Zhang, Y.Q.; Sarge, K.D. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J. Mol. Med., 2007, 85(12), 1421-1428.
111. Fujikake, N.; Nagai, Y.; Popiel, H.A.; Okamoto, Y.; Yamaguchi, M.; Toda, T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem., 2008, 283(38), 26188-26197.
112. Auluck, P.K.; Bonini, N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med., 2002, 8(11), 1185-1186.
113. Kieran, D.; Kalmar, B.; Dick, J.R.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med., 2004, 10(4), 402-405.
114. Ronnen, E.A.; Kondagunta, G.V.; Ishill, N.; Sweeney, S.M.; Deluca, J.K.; Schwartz, L.; Bacik, J.; Motzer, R.J. A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest. New Drugs, 2006, 24(6), 543-546.